This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Taltz
  • /
  • A Dose-Ranging And Efficacy Study of LY2439821 (An...
Clinical trial

A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

Read time: 2 mins
Last updated:1st Apr 2010
Identifier: NCT01107457

The primary purpose for this study is to help answer the following research questions

  • The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
  • Whether ixekizumab can help participants with Psoriasis.
  • How much ixekizumab should be given to participants.
Category Value
Date last updated at source 2015-04-22
Study type(s) Interventional
Expected enrolment 125
Study start date 2010-04-01
Estimated primary completion date 2018-06-01

View full details